GSK PLC ADR (GSK): Price and Financial Metrics

GSK PLC ADR (GSK): $40.15

0.35 (-0.86%)

POWR Rating

Component Grades

Momentum

C

Stability

B

Sentiment

Quality

B

Add GSK to Watchlist
Sign Up

GSK Price/Volume Stats

Current price $40.15 52-week high $43.84
Prev. close $40.50 52-week low $33.33
Day low $40.15 Volume 4,950
Day high $40.15 Avg. volume 3,490,005
50-day MA $42.01 Dividend yield 3.91%
200-day MA $37.71 Market Cap 83.21B

GSK Stock Price Chart Interactive Chart >


GSK PLC ADR (GSK) Company Bio


GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China ResourcesSinopharmJohnson & JohnsonPfizerRocheAbbVieNovartisBayer, and Merck. (Source:Wikipedia)


GSK Latest News Stream


Event/Time News Detail
Loading, please wait...

GSK Latest Social Stream


Loading social stream, please wait...

View Full GSK Social Stream

Latest GSK News From Around the Web

Below are the latest news stories about GSK PLC that investors may wish to consider to help them evaluate GSK as an investment opportunity.

15 Undervalued Defensive Stocks For 2024

In this article, we discuss the 15 undervalued defensive stocks for 2024. To skip the detailed overview of the market and defensive stocks, go directly to the 5 Undervalued Defensive Stocks For 2024. Defensive stocks are shares of companies that remain relatively stable during economic downturns as opposed to cyclical stocks. Defensive stocks usually outperform […]

Yahoo | December 24, 2023

3 Growth at a Reasonable Price (GARP) Stocks for Balanced Growth

GARP stocks are less likely to plunge than growth stocks with high valuations and more likely to generate strong growth than value stocks.

Larry Ramer on InvestorPlace | December 22, 2023

GSK to cut US prices for Advair, Valtrex and Lamictal

The price cuts come after several companies have already announced price decreases for insulins earlier this year as they worked to avoid potential penalties under 2021's American Rescue Plan Act if they had kept prices high. Under the law, drug companies are required to rebate the Medicaid program if price increases on medicines outpace inflation - and beginning in January 2024 those rebates could even be larger than the actual net cost of the drug. According to a GSK spokesman, the company plans to cut list prices by up to 70% on Advair, up to 48% on Lamictal and 10% for Valtrex.

Yahoo | December 22, 2023

Sunak hosts bosses for Business Council gathering

The group agreed there could be more economic growth and dynamism next year, Downing Street said.

Yahoo | December 21, 2023

3 Machine Learning Stocks to Turn $10,000 Into $1 Million: December 2023

Machine learning stocks are ones to watch to unlock value from your portfolio.

Matthew Farley on InvestorPlace | December 14, 2023

Read More 'GSK' Stories Here

GSK Price Returns

1-mo -4.84%
3-mo 1.89%
6-mo 15.71%
1-year 11.67%
3-year 21.13%
5-year 26.88%
YTD 9.37%
2023 9.66%
2022 -16.73%
2021 26.64%
2020 -17.79%
2019 29.12%

GSK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GSK Dividend History

Continue Researching GSK

Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:

Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!